Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bexmarilimab + SoC in MDS, CMML, or AML
NCT05428969Phase 2Active, not recruiting
- Sponsor
- Faron Pharmaceuticals
- Start
- Jun 2022
- Primary completion
- Mar 2027
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 2 trial of bexmarilimab in myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML), acute myeloid leukemia (AML), sponsored by Faron Pharmaceuticals. Started Jun 2022; status: active, not recruiting.
02
Drugs
bexmarilimab
03
Conditions
myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05428969.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05428969.